Komipharm International Co. Ltd (041960) - Net Assets

Latest as of September 2025: ₩74.86 Billion KRW ≈ $50.73 Million USD

Based on the latest financial reports, Komipharm International Co. Ltd (041960) has net assets worth ₩74.86 Billion KRW (≈ $50.73 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩133.65 Billion ≈ $90.57 Million USD) and total liabilities (₩58.79 Billion ≈ $39.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Komipharm International Co. Ltd (041960) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩74.86 Billion
% of Total Assets	56.01%
Annual Growth Rate	4.02%
5-Year Change	-14.08%
10-Year Change	-13.91%
Growth Volatility	16.24

Komipharm International Co. Ltd - Net Assets Trend (2011–2024)

This chart illustrates how Komipharm International Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 041960 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Komipharm International Co. Ltd (2011–2024)

The table below shows the annual net assets of Komipharm International Co. Ltd from 2011 to 2024. For live valuation and market cap data, see Komipharm International Co. Ltd (041960) market capitalisation.

Year	Net Assets	Change
2024-12-31	₩65.54 Billion ≈ $44.41 Million	+9.20%
2023-12-31	₩60.02 Billion ≈ $40.67 Million	-1.02%
2022-12-31	₩60.63 Billion ≈ $41.09 Million	-8.77%
2021-12-31	₩66.46 Billion ≈ $45.04 Million	-12.87%
2020-12-31	₩76.28 Billion ≈ $51.69 Million	+4.09%
2019-12-31	₩73.28 Billion ≈ $49.66 Million	-21.54%
2018-12-31	₩93.39 Billion ≈ $63.29 Million	-7.78%
2017-12-31	₩101.27 Billion ≈ $68.63 Million	+8.65%
2016-12-31	₩93.20 Billion ≈ $63.16 Million	+22.43%
2015-12-31	₩76.13 Billion ≈ $51.59 Million	+43.21%
2014-12-31	₩53.16 Billion ≈ $36.02 Million	+18.87%
2013-12-31	₩44.72 Billion ≈ $30.31 Million	+10.24%
2012-12-31	₩40.56 Billion ≈ $27.49 Million	+3.38%
2011-12-31	₩39.24 Billion ≈ $26.59 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Komipharm International Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 2576.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	₩72.95 Billion	117.13%
Total Equity	₩62.28 Billion	100.00%

Komipharm International Co. Ltd Competitors by Market Cap

The table below lists competitors of Komipharm International Co. Ltd ranked by their market capitalization.

Company	Market Cap
Future Generation Australia Ltd AU:FGX	$380.90 Million
VTEX NYSE:VTEX	$380.90 Million
Puma Biotechnology Inc NASDAQ:PBYI	$381.06 Million
Nexxen International Ltd NASDAQ:NEXN	$381.13 Million
Hyundai Motor S3 Pref KO:005389	$380.79 Million
Berjaya Corporation Bhd KLSE:3395	$380.71 Million
Rajesh Exports Limited NSE:RAJESHEXPO	$380.62 Million
I.C.C. International Public Company Limited BK:ICC	$380.26 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Komipharm International Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 56,337,796,060 to 62,280,266,440, a change of 5,942,470,380 (10.5%).
Net income of 13,113,267,440 contributed positively to equity growth.
Share repurchases of 3,678,487,340 reduced equity.
Other factors decreased equity by 3,492,309,720.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩13.11 Billion	+21.06%
Share Repurchases	₩3.68 Billion	-5.91%
Other Changes	₩-3.49 Billion	-5.61%
Total Change	₩-	10.55%

Book Value vs Market Value Analysis

This analysis compares Komipharm International Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 10.81x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 6.56x to 10.81x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1482.79	₩9720.00	x
2017-12-31	₩1599.65	₩9720.00	x
2018-12-31	₩1468.76	₩9720.00	x
2019-12-31	₩1151.66	₩9720.00	x
2020-12-31	₩1193.90	₩9720.00	x
2021-12-31	₩945.11	₩9720.00	x
2022-12-31	₩864.12	₩9720.00	x
2023-12-31	₩803.07	₩9720.00	x
2024-12-31	₩898.99	₩9720.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Komipharm International Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 21.06%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 22.31%
• Asset Turnover: 0.48x
• Equity Multiplier: 1.97x
Recent ROE (21.06%) is above the historical average (-5.54%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	2.49%	4.57%	0.29x	1.90x	₩-3.05 Billion
2014	-4.04%	-6.24%	0.28x	2.34x	₩-7.47 Billion
2015	-8.60%	-17.99%	0.27x	1.75x	₩-14.16 Billion
2016	0.31%	0.77%	0.25x	1.61x	₩-9.03 Billion
2017	-5.03%	-13.91%	0.25x	1.47x	₩-15.22 Billion
2018	-15.32%	-40.87%	0.25x	1.50x	₩-23.64 Billion
2019	-29.15%	-60.20%	0.28x	1.71x	₩-28.69 Billion
2020	-3.69%	-7.58%	0.30x	1.60x	₩-10.44 Billion
2021	-6.71%	-12.44%	0.31x	1.73x	₩-11.11 Billion
2022	-10.74%	-16.37%	0.36x	1.84x	₩-12.58 Billion
2023	-7.06%	-9.33%	0.36x	2.11x	₩-9.61 Billion
2024	21.06%	22.31%	0.48x	1.97x	₩6.89 Billion

Industry Comparison

This section compares Komipharm International Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $102,887,028,305
Average return on equity (ROE) among peers: 1.10%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Komipharm International Co. Ltd (041960)	₩74.86 Billion	2.49%	0.79x	$380.81 Million
Sam Chun Dang Pharm. Co. Ltd (000250)	$298.46 Billion	-3.48%	0.37x	$6.03 Billion
DongKoo Bio&Pharma Co. Ltd (006620)	$105.33 Billion	1.93%	1.32x	$33.52 Million
NatureCell Co.Ltd (007390)	$39.48 Billion	-1.17%	0.30x	$688.81 Million
Sam-A Pharm. Co. Ltd (009300)	$110.58 Billion	8.88%	0.25x	$68.66 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$169.03 Billion	11.15%	0.19x	$89.89 Million
WooGene B&G Co. Ltd (018620)	$29.85 Billion	-6.92%	1.60x	$13.13 Million
Oscotec Inc (039200)	$26.33 Billion	-13.85%	0.55x	$990.30 Million
EstechPharma Co. Ltd (041910)	$111.39 Billion	9.84%	0.11x	$59.21 Million
Eagle Veterinary Technology Co.Ltd (044960)	$35.53 Billion	3.47%	0.29x	$34.35 Million

About Komipharm International Co. Ltd

KQ:041960 Korea Pharmaceuticals

Market Cap

$380.81 Million

₩561.93 Billion KRW

Market Cap Rank

#13908 Global

#471 in Korea

Share Price

₩9720.00

Change (1 day)

-2.11%

52-Week Range

₩5060.00 - ₩10310.00

All Time High

₩43026.96